Log in
NYSEARCA:PBE

Invesco Dynamic Biotechnology & Genome ETF Stock Forecast, Price & News

$59.58
+0.42 (+0.71 %)
(As of 10/27/2020 12:00 AM ET)
Add
Today's Range
$59.40
Now: $59.58
$59.67
50-Day Range
$53.82
MA: $58.03
$62.28
52-Week Range
$38.08
Now: $59.58
$63.40
Volume3,443 shs
Average Volume10,564 shs
Market Capitalization$229.37 million
P/E RatioN/A
Dividend Yield0.05%
BetaN/A
PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser.
Read More

Geographic Exposure of PBE

Currency Exposure of PBE

Sector Exposure of PBE

Industry Exposure of PBE

Basic Details

Issuer Invesco
Fund NameInvesco Dynamic Biotechnology & Genome ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:PBE
Inception Date6/23/2005
Fund ManagerPeter Hubbard, Michael Jeanette, Tony Seisser, Jonathan Nixon
Phone+1-800-9830903

Fund Focus

Asset ClassEquity
BenchmarkDynamic Biotechnology & Genome Intellidex Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$235.32 million
Average Daily Volume$5,640.00
Discount/Premium-0.02%

ETF Expenses

Management Fee0.50%
Other Expenses0.08%
Total Expenses0.58%
Fee Waiver0.00%
Net Expenses0.58%

Administrator, Advisor and Custodian

AdministratorThe Bank of New York Mellon Corporation
AdvisorInvesco Capital Management LLC
CustodianThe Bank of New York Mellon Corporation
DistributorInvesco Distributors, Inc.
Transfer AgentThe Bank of New York Mellon Corporation
Trustee
Lead Market MakerCitadel
$59.58
+0.42 (+0.71 %)
(As of 10/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PBE News and Ratings via Email

Sign-up to receive the latest news and ratings for PBE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE) Frequently Asked Questions

How has Invesco Dynamic Biotechnology & Genome ETF's stock been impacted by Coronavirus?

Invesco Dynamic Biotechnology & Genome ETF's stock was trading at $45.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PBE shares have increased by 29.8% and is now trading at $59.5757.
View which stocks have been most impacted by COVID-19
.

What other stocks do shareholders of Invesco Dynamic Biotechnology & Genome ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invesco Dynamic Biotechnology & Genome ETF investors own include Pfizer (PFE), Intel (INTC), Align Technology (ALGN), Micron Technology (MU), Activision Blizzard (ATVI), Docusign (DOCU), Inovio Pharmaceuticals (INO), Mastercard (MA), Momo (MOMO) and ONEOK (OKE).

Who are Invesco Dynamic Biotechnology & Genome ETF's key executives?

Invesco Dynamic Biotechnology & Genome ETF's management team includes the following people:
  • H. Bruce Bond, Chairman of the Board of Trustee, Chief Executive Officer
  • Bruce T. Duncan, Chief Financial Officer, Treasurer
  • Kevin R. Gustafson, Chief Compliance Officer
  • Keith A Ovitt, Secretary
  • Ronn R. Bagge, Trustee
  • Marc M Kole, Trustee
  • D. Mark McMillan, Trustee
  • Philip M. Nussbaum Mba, Trustee
  • Donald H. Wilson, Trustee

What is Invesco Dynamic Biotechnology & Genome ETF's stock symbol?

Invesco Dynamic Biotechnology & Genome ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "PBE."

Who are Invesco Dynamic Biotechnology & Genome ETF's major shareholders?

Invesco Dynamic Biotechnology & Genome ETF's stock is owned by many different institutional and retail investors. Top institutional shareholders include Abbot Financial Management Inc. (0.50%), Newman Dignan & Sheerar Inc. (0.36%), Loveless Wealth Management LLC (0.35%), Hills Bank & Trust Co (0.33%) and Flagship Harbor Advisors LLC (0.30%).

Which major investors are selling Invesco Dynamic Biotechnology & Genome ETF stock?

PBE stock was sold by a variety of institutional investors in the last quarter, including Hills Bank & Trust Co, Abbot Financial Management Inc., and Loveless Wealth Management LLC.

Which major investors are buying Invesco Dynamic Biotechnology & Genome ETF stock?

PBE stock was bought by a variety of institutional investors in the last quarter, including Newman Dignan & Sheerar Inc., and Flagship Harbor Advisors LLC.

How do I buy shares of Invesco Dynamic Biotechnology & Genome ETF?

Shares of PBE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Invesco Dynamic Biotechnology & Genome ETF's stock price today?

One share of PBE stock can currently be purchased for approximately $59.58.

How big of a company is Invesco Dynamic Biotechnology & Genome ETF?

Invesco Dynamic Biotechnology & Genome ETF has a market capitalization of $229.37 million.

What is Invesco Dynamic Biotechnology & Genome ETF's official website?

The official website for Invesco Dynamic Biotechnology & Genome ETF is www.invescopowershares.com.

How can I contact Invesco Dynamic Biotechnology & Genome ETF?

Invesco Dynamic Biotechnology & Genome ETF's mailing address is 301 West Roosevelt Road, WHEATON, IL 60187, United States. The company can be reached via phone at +1-800-9830903.

This page was last updated on 10/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.